Hypouricemia in severely disabled children II: influence of elemental enteral nutrition on the serum uric acid levels.
The previous study showed that both valproic acid (VPA) and a bedridden state decreased the serum uric acid level, and VPA-induced renal tubular dysfunction was suspected to be one cause of hypouricemia in severely disabled children. However, it was uncertain what factor of bedridden state influences the uric acid level in severely disabled children. Among many factors of a bedridden state that might influence the uric acid level, we examined the influence of elemental nutrition on the serum uric acid level in severely disabled children because many severely disabled children with marked hypouricemia receive elemental nutrition. Thirty-one severely disabled children were included in this study, who were divided into two groups-group A: 11 patients with elemental nutrition; group B: 20 patients with non-elemental nutrition. The laboratory data in both groups were analyzed statistically, using the t-test. The uric acid level was significantly decreased in group A compared with group B (p < 0.01) without elevation of urinary excretion of uric acid. Other laboratory data, except phosphate and potassium, did not differ between the two groups significantly. An elemental diet may be one factor that decreases the uric acid level in severely disabled children.
Yoshikawa
Hideto
H
Department of Pediatrics, Niigata City General Hospital, 2-6-1 Shichikuyama, Niigata, Japan. hideto@hosp.niigata.niigata.jp
Yamazaki
Sawako
S
Abe
Tokinari
T
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D019988:Children with Disabilities; D004750:Enteral Nutrition; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D005526:Food, Formulated; D006801:Humans; D007223:Infant; D008297:Male; D010710:Phosphates / Q000097:blood; D011188:Potassium / Q000097:blood; D014527:Uric Acid / Q000097:blood*; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D010710:Phosphates; D014527:Uric Acid; D014635:Valproic Acid; D011188:Potassium